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Background: In January 2013, Swaziland launched a prevention
of mother-to-child transmission of HIV (PMTCT) B+ implemen-
tation study in rural Shiselweni. We aimed to identify patient and
health service determinants of combined antiretroviral therapy
(ART) initiation to help guide national implementation of
PMTCT B+.
Methods: This prospective cohort study uses routine data from
registers and patient ﬁles in the PMTCT B+ pilot zone and
a neighboring health zone where PMTCT A was the standard of
care. All HIV-positive women not on combined ART at the ﬁrst
antenatal care visit between January 28, 2013 and December 31,
2013 were included.
Results: 399 women from the PMTCT B+ zone and 183 from the
PMTCT A zone are included. The overall proportion of women who
had not started an antiretroviral intervention before 32 weeks’
gestation was lower in the PMTCT A zone (13% vs 25%, P =
0.003), yet a higher proportion women with CD4 ,350 initiated
combined ART in the PMTCT B+ zone (86% vs 74%, P = 0.032).
Within the PMTCT B+ pilot, initiation rates were highly variable
between health facilities; while at patient level, ART initiation was
signiﬁcantly higher among women with CD4 ,350 compared with
CD4 .350 (80% vs 59%, P , 0.001). Among women with CD4
,350, those recorded as newly diagnosed were more likely to
initiate combined ART. Although lower educational level and
occupational barriers seemed to hinder combined ART initiation
among women with CD4 .350, high proportions of missing socio-
demographic data made it impossible to make any ﬁrm conclusions
to this respect.
Conclusions: This study not only demonstrates challenges in
initiating pregnant women on ART, but also identiﬁes opportunities
offered by PMTCT B+ for improving treatment initiation among
women with lower CD4 counts.
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INTRODUCTION
The use of antiretroviral drugs for prevention of
mother-to-child transmission of HIV (PMTCT) is a well-
established element of HIV programming; several studies
have shown that mono or combined therapy is effective in
protecting the infant from HIV transmission from the mother;
reported transmission rates at 6 months after delivery without
PMTCT range from 25% to 40%, compared with rates of
1%–8% in PMTCT programs.1–3 Since 2010, most countries
have implemented 1 of 2 approaches recommended by the
World Health Organization (WHO). See Figure S1 (Supple-
mental Digital Content, http://links.lww.com/QAI/A628) for
a brief description of these approaches.
In April 2012, the WHO released a programmatic update
that deﬁned a new approach to PMTCT (PMTCT B+), whereby
lifelong combined antiretroviral therapy (ART) is offered to
all pregnant and breastfeeding women with HIV, irrespective
of CD4 count or WHO Clinical Stage.4 This approach is
thought to offer a number of advantages: it is operationally
simpler (the same treatment for everyone, no delay when
CD4 testing absent); reduced risk of mortality and disease
progression (HIV-related and Hepatitis B) associated with
treatment interruptions; reduced risk of mother-to-fetus trans-
mission in the next pregnancy from the moment of concep-
tion; and reduced risk of transmission to a seronegative
partner.4,5 Furthermore, it may be beneﬁcial to the health of
the mother in the light of emerging evidence on reduced
mortality among mothers treated with lifelong ART at CD4
counts above 350.6,7
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Swaziland has a robust PMTCT programme based on
the PMTCT Option A approach. Although antenatal HIV
prevalence is amongst the highest in the world (37% in
2012),8 over 80% of HIV+ pregnant women receive anti-
retroviral prophylaxis (zidovudine) or combined ART.8
Mother-to-child transmission is low at 6 weeks postpartum
(2%–3%), although cumulative mother-to-child transmission
rates at 18 months remain high at 12%–15%.9 Challenges of
adherence to nevirapine for the long breastfeeding period (17
months on average), has been suggested as a possible cause.9
An additional challenge for HIV care for pregnant women in
Swaziland was highlighted in the 2012 Annual PMTCT report
from 2012, showing that approximately half of the HIV+
pregnant women eligible for lifelong combined ART accord-
ing to the national guidelines (CD4,350 or WHO stages III/
IV) were treated with prophylactic therapy only.10 Failure to
initiate lifelong ART puts these women at increased risk of
HIV/AIDS-related morbidity and mortality; therefore, there
is signiﬁcant national interest in whether PMTCT B+ can
help improve initiation rates among this population. Devel-
oping appropriate health messages around PMTCT B+ is
particularly challenging, because previous messages declared
that if one’s CD4 count was greater than 350, they did not
need antiretroviral treatment. In Swaziland, zidovudine is
often presented to the patient as not being an ART.11
Whether women who were not previously eligible for
treatment will initiate combined ART, and what factors
inﬂuence initiation of combined ART, are important ques-
tions for health programmers.
In January 2013, Médecins sans Frontières (MSF), in
collaboration with the Swaziland National AIDS Programme,
implemented PMTCT B+ in 1 health zone in the Shiselweni
region as a pilot program. In light of the pilot and the WHO
guidance recommending PMTCT B+ in settings with high
prevalence and high birth rate, the Ministry of Health in
Swaziland will roll out PMTCT B+ as national strategy in
2014.12 This article reports on the early implementation
experience of PMTCT B+ in Swaziland, drawing lessons
learnt that can guide implementation of this approach
nationally, and elsewhere.
METHODS
Design
A prospective cohort study of women found to be HIV-
positive (newly diagnosed or known HIV+ status but not
already on treatment) at the ﬁrst antenatal care (ANC), in
a health zone implementing PMTCT B+ and a neighboring
health zone where PMTCT A is the standard of care.
Setting
Swaziland is a landlocked lower–middle-income coun-
try in Southern Africa, with a population of 1.2 million and an
HIV prevalence among 18- to 49-year-olds of 31%.13 This
study is carried out in Shiselweni region, which constitutes
25% of the geographical area of the country and has
a relatively poor and rurally located population of 210,000.
Every year, approximately 2000 HIV+ pregnant women
access ANC in the region.8 Nearly all health care facilities
offering ANC in the region are equipped with point-of-care
CD4 technology (Alere PimaTM, Waltham, Massachusetts,
USA).
In January 2013, PMTCT B+ was introduced as a pilot
program in Nhlangano, 1 of 3 health zones in Shiselweni. This
study uses routine data from ANC records in all facilities
providing PMTCT B+ in Nhlangano zone and all facilities
providing PMTCT A in the neighboring health zone of
Hlathikhulu (9 facilities per health zone). Prophylactic therapy
(zidovudine for the mother, nevirapine for the baby) was offered
to women refusing combined ART in the PMTCT B+ zone. At
the start of the pilot study, same-day initiation of combined ART
was not encouraged. However, after 3 months, it was noted that
median time to ART initiation was well over the 1-week target,
and a decision was made to adapt the standard operating
procedures (SOPs) in favour of same-day initiation for women
who were ready. Details of the PMTCT B+ implementation
process in Shiselweni and copies of the adapted SOPs are
available online (see Information S1 & S2, Supplemental Digital
Content, http://links.lww.com/QAI/A628).
Participants and Data Collection
Between January 28, 2013 (the start of the pilot study)
and December 31, 2013, all women presenting for their ﬁrst
ANC within the study zone who tested HIV+ for the ﬁrst
time, or who already knew their HIV+ status but were not yet
on combined ART, were included in the study. Women who
were diagnosed HIV+ at subsequent ANC visits by repeat
testing were eligible for combined ART within the PMTCT B
+ pilot zone but were not included in this study. For the study
participants, routine data were collected from the eighteen
health structures. Baseline characteristics (the ﬁrst ANC visit
date, maternal age, gestational age at ﬁrst ANC, CD4 count,
WHO clinical stage, and combined ART/zidovudine initiation
date) were obtained from ANC registers by MSF data clerks.
For women who initiated combined ART, time to ART
initiation was calculated as the difference between combined
ART initiation date and ﬁrst ANC date. Women who initiated
ART before 32 weeks’ gestation were considered to have
successfully initiated (for the purposes of PMTCT); for
women whose ﬁrst ANC consultation was 32 weeks or later,
initiation was considered successful if it took place within 7
days (the national target for ART initiation in PMTCT
programmes). Combined ART initiation was validated with
the ART article register, and patient ﬁles were retrieved to
obtain data on marital status, occupation, educational level,
and disclosure status.
Data Analysis
We compared the proportion of eligible patients
initiating combined ART in the 2 health zones and the
proportion initiating amongst patients with CD4 ,350 or
WHO Stage III/IV disease. Within the PMTCT B+ zone, we
compared characteristics of those who initiated combined
ART and those who did not, including a variable indicating
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whether the patient attended the ﬁrst ANC before or after the
SOPs were switched in favour of same-day initiation. Pearson
x2 test was used to test for association between categorical
variables, and a nonparametric K-sample median test was
used for continuous variables with asymmetrical distributions.
In the comparison of ART initiation before and after the
implementation of same-day initiation, data from a facility
where staff problems led to signiﬁcant changes in combined
ART use during the latter period were excluded to reduce the
chance of bias. Socio-demographic characteristics were not
available for all patients because of incomplete and inconsis-
tent data recording at facility level. Statistical tests in Tables 1
and 2 are reported excluding missing values.
We also explored the barriers and facilitators to ART
initiation in the PMTCT B+ zone using unconditional logistic
regression. Adjusted odds ratios (ORs) and 95% conﬁdence
intervals (95% CI) were calculated using an unconditional
multivariable regression model developed in a stepwise back-
ward manner. Variables that were associated with uptake in
univariable analysis with a P , 0.10 were considered for
inclusion in the model. Educational level, occupation, marital
status, and disclosure status were excluded from multivariable
analysis because of the high proportion missing socio-
demographic information. Because of effect modiﬁcation,
separate models were evaluated for women with CD4 ,350
and women with CD4 .350. Models were controlled for
clustering by health facility. Data entry was carried out using
Epidata 3.1, and data analysis used Stata/SE 12 (StataCorp,
College Station, TX).
Ethics
Ethical approval for this study was granted by the
Scientiﬁc and Ethics Committee of the Ministry of Health of
Swaziland, and the International Ethics Review Board
instituted by MSF. Informed consent for study participation
was not solicited from participants, and only routinely
collected data were used.
RESULTS
Comparison PMTCT B+ and PMTCT A
Health Zones
Five hundred eighty-two women were included in the
analysis: 399 (69%) from the PMTCT B+ health zone and
183 (31%) from the PMTCT A health zone. Baseline
characteristics of the women are shown in Table 1. Their
median age was 25 years [interquartile range (IQR), 22–29
years], the median CD4 was 411 (IQR, 288–558), and the
median gestational age at ﬁrst ANC was 21 weeks (IQR, 17–
25). More than half of the women were recorded as newly
diagnosed HIV-positive at ﬁrst ANC consultation. The pro-
portion of newly diagnosed individuals and the proportion of
women with CD4 ,350 cells per milliliter were higher in
PMTCT B+ zone compared with the A zone (64% vs 54%,
P = 0.020; and 37% vs 29%, P = 0.033, respectively). In
terms of PMTCT, the proportion of women who had not
started any form of antiretroviral intervention (either zidovu-
dine or combined ART) before 32 weeks’ gestation was
higher in the PMTCT B+ zone, where 98 (25%) women had
not initiated combined ART or zidovudine, compared with 23
(13%) in the PMTCT A zone (P = 0.003). Amongst the
subgroup of women with CD4 counts below 350 cells per
milliliter, combined ART initiation was higher in the PMTCT
B+ zone [128 (86%) compared with 39 (74%) in the PMTCT
A zone (P = 0.032)]. The median time to combined ART
initiation was 7 days (IQR, 0–28 days) in both zones.
ART Initiation in the PMTCT B+ Zone
The level of combined ART initiation varied signiﬁ-
cantly between facilities ranging from 38% to 89%
(P = 0.003, Table 2). Median time to combined ART
initiation in the PMTCT B+ zone was 8 days (IQR, 5–31)
before implementation of same-day initiation and 0 days
(IQR, 1–14 days) (P , 0.001) afterward. Although the
proportion of pregnant women initiating combined ART did
improve slightly with each quarter (Table 2), the overall
TABLE 1. Baseline Characteristics and ART Uptake Among HIV
women at First ANC in Nhlangano and Hlathikhulu Zones,
Shiselweni, Jan–Dec 2013
Nhlangano Health
Zone (PMTCT B+)
(N = 399)
Hlathikhulu Health
Zone (PMTCT A)
(N = 183) P*
HIV status
knowledge, N (%)†
Known status 143 (36) 84 (46) 0.020
Newly diagnosed 254 (64) 98 (54)
Median age, yrs (IQR) 25 (22–30) 25 (22–29) 0.809
Median Gestational
age, wks (IQR)
21 (17–26) 22 (17–26) 0.314
CD4 count, N (%)
,350 148 (37) 53 (29) 0.033
$350 201 (50) 110 (60)
Missing CD4
information
50 (13) 20 (11)
MTCT prophylaxis,
N (%)
On combined ART
at 32 wks’
gestation
252 (63) 43 (23) ,0.001
On zidovudine at
32 wks’
gestation
49 (12) 117 (64)
Not on combined
ART or
zidovudine at 32
wks’ gestation
98 (25) 23 (13)
ART uptake‡ among
women CD4 ,350,
N (%)
Initiated combined
ART
128 (86) 39 (74) 0.032
*P values shown are from Pearson x2 test, except for age, which was from
a nonparametric K-sample median test.
†Three individuals had missing information on HIV status knowledge: 2 in the
PMTCT B+ zone and 1 in the PMTCT A zone.
‡Uptake of combined ART at any gestational age.
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initiation rates remained below the programme target of 80%.
The proportion of women initiating combined ART was
higher after implementation of same-day initiation and
revision of clinical SOPs (60% before, vs 70% after the
intervention, P = 0.045). Initiation rates were signiﬁcantly
lower among women with higher CD4 counts (59% of
women with CD4 .350 initiated combined ART before 32
weeks compared with 80% of women with CD4 ,350, P ,
0.001, OR adjusted for clustering be health facility = 0.37,
95% CI: 0.26 to 0.52). Age did not seem to be associated
with initiating combined ART; the median age of the women
who started combined ART was 25 (IQR, 22–30) years
compared with 24 (IQR, 23–29) years in those who did not
start combined ART (P = 0.494). The impact of other
patient-level barriers and facilitators of combined ART
initiation seemed to be different among the 2 CD4 groups
and are described separately in Table 2.
Barriers and Facilitators of ART Initiation
Among Women With CD4 .350 in the
PMTCT B+ Zone
A large proportion of the women with CD4 .350 had
missing information for educational level, occupation, martial
status, and disclosure status (119, 59%; 108, 54%; 93, 46%;
and 120, 60%, respectively) preventing analysis of the impact
of these factors on combined ART initiation with a high degree
of validity. However, we observed that among women with
TABLE 2. Clinical and Socio-demographic Characteristics Influencing ART Initiation for PMTCT B+ According to CD4 Count at
First ANC Consultation
Total (N = 399) CD4 ,350 (N = 148) CD4 ‡350 (N = 201) CD4 Missing (N = 50)
ART Uptake, N (%)* P† ART Uptake, N (%)* P† ART Uptake, N (%)* P† ART Uptake, N (%)* P†
Overall 252 (63) 118 (80) 119 (59) 15 (33)
HIV status knowledge‡
Known status 96 (67) 0.226 48 (87) 0.074 39 (58) 0.792 9 (43) 0.091
Newly diagnosed 155 (61) 69 (75) 80 (60) 6 (21)
Date of ﬁrst ANC
Q1 2013 53 (59) 0.452 23 (77) 0.912 28 (58) 0.425 2 (17) 0.423
Q2 2013 79 (60) 34 (79) 38 (52) 7 (44)
Q3 2013 78 (67) 44 (80) 31 (63) 3 (23)
Q4 2013 42 (69) 17 (85) 22 (69) 3 (33)
Facility
1 10 (66) 0.003 5 (71) 0.020 4 (57) 0.350 1 (100) 0.559
2 16 (89) 9 (100) 7 (88) —
3 8 (38) 2 (40) 6 (40) 0 (0)
4 22 (73) 10 (91) 12 (67) 0 (0)
5 16 (67) 7 (88) 8 (62) 1 (33)
6 122 (69) 61 (85) 58 (62) 3 (25)
7 23 (59) 7 (88) 11 (69) 5 (33)
8 23 (44) 14 (67) 6 (35) 3 (21)
9 12 (55) 3 (43) 7 (58) 2 (67)
Educational status§
Less than Secondary 90 (70) 0.061 49 (83) 0.454 35 (58) 0.018 6 (67) 0.858
Secondary completed 42 (84) 18 (90) 19 (86) 5 (62)
Occupation§
Unemployed 86 (83) 0.019 37 (90) 0.319 46 (84) ,0.001 3 (38) 0.027
In paid employment 47 (68) 24 (77) 17 (53) 6 (100)
Self-employed 8 (89) 5 (100) 3 (100) 0 (0)
Housewife 3 (42) 3 (75) 0 (0) 0 (0)
Marital status§
Married 50 (83) 0.115 23 (85) 0.989 23 (82) 0.083 4 (80) 0.457
Single 117 (73) 58 (85) 51 (65) 8 (62)
Disclosure Status§
Disclosed to family 89 (82) 0.037 40 (93) 0.011 44 (77) 0.111 5 (63) 0.248
Undisclosed to family 41 (68) 19 (70) 15 (60) 7 (88)
*The percentages shown here are the proportion of women who initiated ART in each subgroup (row percentage). Although the denominator is not shown in this table, it can
deduced, eg, the number of women with a known status 0.63 * 96 = 143 (for total column, the information is also available in Table 1).
†P values shown are from Pearson x2 test except for age, which was from a nonparametric K-sample median test.
‡Two individuals had missing information on HIV status knowledge: one had CD4 ,350 and initiated ART, and the other had CD4 .350 and did not initiate ART.
§Socio-demographic details were missing for a high proportion of patients: education (n = 221, 55%), employment (n = 226, 57%), marital status (n = 179, 45%), and disclosure
status (n = 232, 58%).
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available socio-demographic information and CD4 .350,
uptake was signiﬁcantly higher among women with at least
secondary education completed, compared with women with
less than secondary education (86% vs 58%, P = 0.018,
Table 2). Furthermore, women in paid employment had lower
initiation rates than those who were unemployed (53% vs 83%
respectively, P , 0.001).
Barriers and Facilitators of ART Initiation
Among Women With CD4 ,350 in the
PMTCT B+ Zone
There were also high levels of missing socio-
demographic information for women with lower CD4 counts
(education: 69, 46%; occupation: 67, 45%; marital status: 53,
36%; and disclosure status: 77, 52%). However, in contrast to
women with high CD4 counts, among the women with
available socio-demographic data, the impact of education,
employment, or marital status seemed to be minimal (Table
2). In this group, a higher proportion of women who had
disclosed their status to their family initiated ART compared
with those who had not disclosed (93% vs 70%, P = 0.011).
Furthermore, women who knew their HIV+ status before
attending their ﬁrst ANC seemed more likely to start ART for
PMTCT compared with women who were newly diagnosed at
the ANC appointment, but this did observation did not reach
statistical signiﬁcance (87% vs 75%, P = 0.074).
Missing Data
Socio-demographic information (education, employ-
ment, and marital status) and disclosure status were obtained
from patient ﬁles. Two hundred sixty-two (66%) of the
women in the study had missing socio-demographic infor-
mation, and these women were less likely to have started
combined ART compared with those with socio-demographic
information available (OR, 0.4; 95% CI: 0.2 to 0.6).
Furthermore, the disclosure status was not noted for 232
(37%) of the women; similarly, these women were less likely
to have started ART compared with those with a disclosure
status recorded (OR, 0.3; 95% CI: 0.2 to 0.5).
DISCUSSION
We observed higher rates of initiation of combined
ART among pregnant women with CD4 ,350 cells per
milliliter in the PMTCT B+ setting, relative to a compara-
ble setting where PMTCT A was the standard of care.
Because the majority of HIV/AIDS-related morbidity and
mortality in pregnancy and the postnatal period occurs in
the CD4 ,350 group, these ﬁndings demonstrate the
potential of PMTCT B+ to reduce HIV-related mortality
and morbidity.14 However, it was also noted that fewer
women in the PMTCT B+ zone received an antiretroviral
treatment before 32 weeks’ gestation than those in the
PMTCT A zone, which could result in an increased risk of
vertical transmission during pregnancy and delivery.
Although initiating antiretroviral treatment is no guarantee
of adherence, effectiveness of PMTCT B+ must start with
high levels of combined ART uptake. Attention must be
paid to reinforcing counseling around beneﬁts of combined
ART for PMTCT, and ongoing training and support of
health workers is needed to ensure that high rates of
initiation are maintained during the transition from
PMTCT A to PMTCT B+.
The rate of combined ART initiation in the context of the
PMTCT B+ pilot program was below 80%, mainly because of
lower initiation rates among women with high CD4 counts.
However, the levels of ART uptake varied remarkably between
different facilities regardless of the CD4 group. Given that this
was a new pilot program, it is likely that the level of
understanding and acceptance of this new approach varied
between facilities, which could explain the varying results
observed. This would be expected to improve with time.
Although health system barriers have been perceived as
barriers for ART initiation for PMTCT in other studies,15 it
should be noted that these ﬁndings differ signiﬁcantly from
implementation experiences in Malawi, where much higher
rates of ART initiation were described during PMTCT B+ roll-
out.16 This difference in itself suggests that key determinants of
combined ART initiation are health system–related. In Malawi,
PMTCT B+ was implemented on a nationwide basis; sensiti-
zation and mobilization process was led by the Ministry of
Health, using all available communication media. By contrast
in Swaziland, mass media could not be used to communicate
about PMTCT B+, because PMTCT A is still a national
strategy. Furthermore, the ongoing availability of prophylactic
treatment with zidovudine in Swaziland enables health workers
and patients who are skeptical of combined ART to use this
“lighter option,” often perceived in Swaziland as not being an
ART at all.11
It is also important to note that, unlike Malawi, ANC
facilities in Shiselweni have point-of-care CD4 testing such
that CD4 results are available within 20 minutes of testing.
Although not required for combined ART initiation for
PMTCT B+, availability of CD4 results may impact both
the nurses’ and the patients’ behavior, given that CD4 level
has previously been presented as the principal criterion for
ART initiation. Low levels of ART initiation among women
with high CD4 counts could reﬂect the focus of health
workers on initiating ART in patients with low CD4 counts,
known to be most in need of treatment, in accordance with
previous training they have received. Moreover, it could
reﬂect the patients’ sense that they are still well and thus can
wait to start combined ART, in line with messages previously
transmitted by health workers.11
The same-day ART initiation seemed to be an
important contributor to the successful introduction of
PMTCT B+ in the study zone. Discussions with individual
patients (who did and did not initiate combined ART)
revealed that many were open to initiate combined ART
the same day but were told by the health worker to go back
home and think about it.11 However, attention must be paid
to treatment education and support when introducing same-
day initiation to ensure that attrition rates remain acceptable.
Recent ﬁndings from Malawi suggest that pregnant women
testing HIV-positive and starting ART on the same day are
particularly at risk of attrition.17
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The implementation approach and health facility–
related factors were the principal but not the sole determinants
of ART initiation. Although high levels of missing data made
the analysis of the inﬂuence of some patient-level factors
extremely challenging, it did seem that they varied according
to whether the patient’s CD4 level was below or above the
threshold for combined ART eligibility (350 cells/mL), used
nationally in Swaziland. In those with CD4 counts below 350,
nondisclosure of HIV status to family could be a potential
barrier to initiation, which has been described in other studies
in general HIV+ populations.18,19 We also observed higher
rates of ART initiation among women with lower CD4 counts
who knew they were HIV-positive before coming to ANC. It
is possible that the message from previous visits about the
need to start ART when the CD4 count was below 350
facilitated combined ART initiation among these women,
whereas newly diagnosed women may have needed more
time to come to terms with their diagnosis and thus may not
have been ready to initiate ART promptly. Interpreting the
differences in combined ART uptake according to education,
occupation, and marital status is difﬁcult because a large
proportion of missing data may have introduced bias into the
study. However, among women with available socio-
demographic data and higher CD4 counts, initiation rates
were the lowest amongst women of a lower education level,
which could suggest a barrier in the understanding of the
information given during counseling. Similarly, among those
with high CD4s and available socio-economic information,
initiation rates were lower for women in paid employment
(mostly factory workers) compared with unemployed people.
This could reﬂect strict working conditions and a low level of
workplace autonomy making it difﬁcult for these women to
attend appointments. In light of difﬁculties interpreting data
with a high proportion of missing data, it is worth noting that
the observations made here are in line with other studies
describing status knowledge, nondisclosure, educational and
occupational barriers to ART initiation and adherence.20,21
This study included consecutively recruited women
attending ANC facilities in 2 health zones in rural Swaziland.
There was an imbalance in the study population such that the
intervention zone had more than double the sample size of the
comparison zone. Although we recognise that the reduced
sample size in the PMTCT A zone reduces the statistical
power of the comparisons shown in Table 1, we believe that
the impact on our results was minimal. This study was carried
out using data available from routine clinical registers and
patient ﬁles. Approximately 10% of the participants had
missing information on CD4 count. This was in part caused
by unreliable access to a functioning PIMA machine in 2 of
the facilities (1 in each zone) but may also have been due to
poor record-keeping in some facilities. We had a higher
volume of missing socio-economic information, and because
of differences in recording and ﬁling for pre-ART patients in
some facilities, these data were less likely to be available for
women who did not initiate ART. Hence, missing data were
not equally distributed among those initiating and those not
initiating ART. This could introduce bias to the study and
limit the internal validity of the ﬁndings. We might expect
those who have complete records to be different from those
with incomplete records (eg, women with complete records
may have better access to health care, may be more educated,
or may face less work-related barriers). Given these limita-
tions, we urge readers to interpret any of the associations
regarding disclosure, educational status, occupation, and
marital status with the utmost caution. The issue of missing
data highlights the challenge of evaluating programmes using
routine data sources, especially in low-resource settings,
where a high level of decentralization and task shifting makes
detailed comprehensive monitoring and evaluation challeng-
ing. Comprehensive recording and data quality should be an
important operational concern for national programmes that
wish to roll out PMTCT B+.
In conclusion, implementing PMTCT B+ where
PMTCT A remains national strategy is challenging but
feasible. This study not only demonstrates barriers to
initiating pregnant women on combined ART, but also
identiﬁes opportunities offered by PMTCT B+ for improving
initiation rates among women with lower CD4 counts.
Overall, the uptake of combined ART during the ﬁrst year
of Swaziland’s PMTCT B+ pilot was suboptimal, mainly
because of poorer initiation rates among women with higher
CD4s. The predominant barriers to ART initiation seem to be
health service–related, but efforts may still be needed to
overcome occupational barriers faced by some women and to
ensure that messages about beneﬁts of early ART initiation
reach women with lower educational level. Offering same-
day initiation for pregnant women who are ready to do so
seems to be vital to ensure optimal rates (and timeliness) of
ART initiation. These ﬁndings will help guide nationwide
implementation of PMTCT B+ in Swaziland in 2014 and can
be useful for similar, high-prevalence low-resource settings
making a switch to PMTCT B+.
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